MM patient characteristics (n = 48)
| Parameter . | MM patients . |
|---|---|
| Age, median (range), y | 69 (25-92) |
| Males | 25 (52) |
| Disease stage | |
| ND, no prior therapy | 13 (27) |
| RR, ≤3 lines of therapy | 14 (29) |
| RR, >3 lines of therapy | 20 (42) |
| RR, unclassifiable | 1 (2) |
| Last exposure to therapy | |
| ND, no prior therapy | 13 (27) |
| Last exposure date unknown | 4 (8) |
| Last exposure > 1 mo | 14 (29) |
| Last exposure ≤ 1 mo | 17 (36) |
| IMiD, n | 8 |
| PI, n | 1 |
| IMiD + PI, n | 2 |
| Daratumumab, n | 6 |
| Parameter . | MM patients . |
|---|---|
| Age, median (range), y | 69 (25-92) |
| Males | 25 (52) |
| Disease stage | |
| ND, no prior therapy | 13 (27) |
| RR, ≤3 lines of therapy | 14 (29) |
| RR, >3 lines of therapy | 20 (42) |
| RR, unclassifiable | 1 (2) |
| Last exposure to therapy | |
| ND, no prior therapy | 13 (27) |
| Last exposure date unknown | 4 (8) |
| Last exposure > 1 mo | 14 (29) |
| Last exposure ≤ 1 mo | 17 (36) |
| IMiD, n | 8 |
| PI, n | 1 |
| IMiD + PI, n | 2 |
| Daratumumab, n | 6 |
Unless otherwise noted, data are n (%).